Marti Technologies Inc. (MRT)
AMEX AMEX Primary 
Monte Rosa's MRT-8102 Shows Biomarker Gains in GFORCE-1 Study
Monte Rosa Therapeutics NASDAQ: GLUE reported results from GFORCE-1, a Phase I study of its NEK7-directed molecular glue degrader MRT-8102 in participants with elevated cardiovascular risk. The company said the four-week dosing study showed sustained degradation of NEK7, reductions in inflammatory and atherogenic biomarkers, and a safety profile comparable with placebo.
Marti Technologies: Buy The Inflection Point
Marti Technologies (MRT) delivered a major operating inflection, turning adjusted EBITDA positive and expanding gross margin to 77%, while accelerating revenue growth. I maintain a speculative buy rating with a $3.88 price target, but highlight that convertible debt implies upside should be viewed on a fully diluted basis. Regulatory uncertainty, balance sheet risks, and potential competition threaten margins and limit de-risking despite strong operating momentum and city expansion.
Marti Technologies, Inc. (MRT) Q2 2026 Earnings Call Transcript
Marti Technologies, Inc. (MRT) Q2 2026 Earnings Call Transcript
Marti Technologies H1 Earnings Call Highlights
Marti Technologies NYSEAMERICAN: MRT reported second-quarter 2026 revenue growth of 141% year over year to nearly $20 million and reached positive adjusted EBITDA for the first time, as its ride-hailing marketplace expanded and costs rose more slowly than revenue.
Marti Is Highly Risky, Financially And Operationally
Marti Is Highly Risky, Financially And Operationally
Marti Technologies, Inc. (MRT) Q1 2026 Earnings Call Transcript
Marti Technologies, Inc. (MRT) Q1 2026 Earnings Call Transcript
Marti: A Potential Early-Stage Opportunity Has Emerged
Marti Technologies, Inc. (MRT) offers hyper-growth exposure to Turkey's e-hailing and mobility market, combining ride-hailing, delivery, and self-use fleet services. MRT's 2025 revenue grew 110.3% year-over-year, with adjusted EBITDA margin improving from -104% to -31%, signaling early operating leverage and monetization progress. Management guides for 2026 revenue of $70 million and positive adjusted EBITDA, supported by rapid ride growth and SG&A stabilization.
Marti Technologies, Inc. (MRT) Q4 2025 Earnings Call Transcript
Marti Technologies, Inc. (MRT) Q4 2025 Earnings Call Transcript
Monte Rosa Therapeutics: Competitive MRT-8102 Results Offer Additional Platform Validation
Monte Rosa Therapeutics delivered strong interim phase 1 results for MRT-8102, showing deep NEK7 degradation and competitive hsCRP reductions in cardiovascular risk patients. The results further validate its molecular glue degrader platform and position MRT-8102 as an upstream approach versus IL-1/IL-6 targeting biologics. Results of MRT-2359 in heavily pretreated patients with metastatic castration-resistant prostate cancer are inconclusive.
Monte Rosa: Looking Mispriced After Big Pharma Validation
Monte Rosa Therapeutics (GLUE) is transitioning from an oncology focus to a next-gen immunology & inflammation (I&I) platform, with significant pharma partnerships. GLUE's pipeline features MRT-6160 (VAV1 degrader, partnered with Novartis), MRT-8102 (NEK7 degrader), and MRT-2359 (oncology), offering both I&I and oncology upside. Strong financial position with ~$400M cash, multiple lucrative deals with Novartis and Roche, and a cash runway through 2028 reduce near-term dilution risk.
Marti Technologies, Inc. (MRT) Q2 2025 Earnings Call Transcript
Marti Technologies, Inc. (NYSE:MRT ) Q2 2025 Earnings Call September 22, 2025 8:30 AM EDT Company Participants Oguz Oktem - Founder, CEO & Chairman Cankut Durgun Conference Call Participants Theodore O'Neill - Litchfield Hills Research, LLC John Halpert - Cantor Fitzgerald & Co., Research Division Rohit Kulkarni - ROTH Capital Partners, LLC, Research Division Yanfang Jiang - The Benchmark Company, LLC, Research Division Siddharth Havaldar Presentation Operator Hello, everyone, and thank you for joining us for Marti Technologies First Half 2025 Conference Call. Before we begin, I'd like to mention that today's earnings release and slide presentation are available on Marti's Investor Relations website at ir.marti.tech, where you will also find links to our SEC filings, along with other information about Marti.
Monte Rosa: H1 2026 NEK7 Protein Degrader MRT-8102 Data Could Be Added POC
Monte Rosa secured a second major Novartis deal, adding $120M upfront and up to $5.7B in milestones to its cash reserves. GLUE advances MRT-8102, a NEK7 molecular glue degrader, into Phase 1 trials targeting inflammatory and cardio-immunology disorders, with key data expected in H1 2026. Strong financial position with $295.5M in cash as of June 2025, supported by multiple big pharma collaborations, funding operations into 2028.
